Study finds <1% of prescriptions that violate black box warningscause adverse drug events
An observational study of 51 outpatient practices found that about7 in 1,000 outpatients were administered a prescription thatviolated an FDA black box warning and that <1% of those patientshad an adverse drug event (ADE) as a result.
An observational study of 51 outpatient practices found that about 7 in 1,000 outpatients were administered a prescription that violated an FDA black box warning and that <1% of those patients had an adverse drug event (ADE) as a result.
The study, published in the Archives of Internal Medicine, involved 40 hospital-based clinics, 4 community health centers, and 7 community-based practices in the Boston, Mass, region in 2002 and tested the frequency of adverse drug-drug, drug-laboratory, and drug-disease interactions among patients by examining electronic health records (EHRs).
"Although a few outpatients seem to receive prescriptions in violation of black box warnings for drug-drug, drug-laboratory, and/or drug-disease interactions, the absolute number of outpatients at risk is substantial," the authors stated.
After multivariate analysis, researchers found patients most likely to receive medications in violation of a black box warning were aged ≥75 years (OR=1.94; 95% CI, 1.08–3.48; P<.05), female (OR=1.37; 95% CI, 1.25–1.50; P<.05), receiving care from a community health center (OR=1.89; 95% CI, 1.05–3.39; P<.05) or a hospital-based clinic (OR=1.79; 95% CI, 1.02–3.12; P<.05), and had ≥7 medical problems on their EHRs when the medication with the black box warning was prescribed (OR=1.93; 95% CI, 1.30–2.86; P<.05).
To measure the frequency of ADEs, the EHRs of a random sample of 575 patients who received a medication in violation of the black box warning were reviewed. Among the 575 patients, a total of 583 warning violations were identified. After excluding 92 apparent violations because the medication was not given in violation of the black box warning and an additional 124 cases because insufficient data were available in order to determine whether an ADE had occurred, a total of 367 black box warning violations were examined.
Four ADEs related to black box warning violations were identified (1.1%; 95% CI, 0.03%–2.15%; P<.05) with an additional 92 potential ADEs (25.1%; 95% CI, 20.6%–29.5%; P<.05) and 154 medication errors (42.0%; 95% CI, 36.9%–47.0%; P<.05) identified by researchers. Four ADEs were not related to a black box warning violation (1.1%; 95% CI, 0.03%–2.15%; P<.05).
The drug most often prescribed in violation of its black box warning was propoxyphene, which had 115 cases (31.3%) resulting in 2 ADEs. Other drugs associated with frequent black box warning violations included azathioprine, carbamazepine, lithium carbonate or citrate, metformin, triamterene, and valproate. The seven drugs accounted for a total of 1,745 black box warning violations (74.1%).
A limitation identified by the authors was the lack of access to patient data beyond that which was contained in their EHRs. Consequently, whether an ADE had occurred in a subject could not be determined in approximately 20% of the random sample analyzed, thus causing potential underestimation of ADEs as outpatients may not have reported symptoms caused by an ADE while receiving care.
According to researchers, the "vague" wording of some black box warnings needs to be clarified to diminish ADE risk, especially with the expected spread of computerized means to track patients' health history. In their initial univariate analysis, researchers found that 1,486 prescriptions (59.8%; P<.001) in violation of black box warnings were given by either primary care medical doctors, nurse practitioners, or physician assistants.
"The Food and Drug Administration should make these warnings more specific, so they are readily understandable by providers, and so that such providers can easily take action to avoid violating the warnings," the authors stated. "Because of the increasing use of EHRs, the warnings should be mapped to terms that make them computable."
Prior studies cited by the researchers obtained startlingly different results, demonstrating that prescribers "fail to adhere to black box warnings much more frequently than was observed in our study."
SOURCE Lasser KE, Seger DL, Yu DT, et al. Adherence to black box warning for prescription medications in outpatients. Arch Intern Med. 2006;166: 338–344.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
